This biomarker is widely used to make decisions on whether to start or change treatment for prostate cancer, but PCWG3 recommendations establish that PSA progression should not be defined before week 12 because of flare phenomenon or late response [2,3,4]. The gene discussed is KLK3; the disease is prostate carcinoma.